CY1120891T1 - Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια - Google Patents

Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια

Info

Publication number
CY1120891T1
CY1120891T1 CY181101171T CY181101171T CY1120891T1 CY 1120891 T1 CY1120891 T1 CY 1120891T1 CY 181101171 T CY181101171 T CY 181101171T CY 181101171 T CY181101171 T CY 181101171T CY 1120891 T1 CY1120891 T1 CY 1120891T1
Authority
CY
Cyprus
Prior art keywords
microparticles
pharmaceutical composition
microns
slow release
active substance
Prior art date
Application number
CY181101171T
Other languages
English (en)
Inventor
Bertrand Ducrey
Patrick Garrouste
Catherine Curdy
Marie-Anne Bardet
Hervé Porchet
Eija Lundstrom
Frédéric Heimgarten
Original Assignee
Debiopharm Res & Manufacturing Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120891(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debiopharm Res & Manufacturing Sa filed Critical Debiopharm Res & Manufacturing Sa
Publication of CY1120891T1 publication Critical patent/CY1120891T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Φαρμακευτική σύνθεση κατασκευασμένη από μικροσωματίδια για την αργή αποδέσμευση μίας δραστικής ουσίας τουλάχιστον κατά τη διάρκεια μίας περιόδου που καλύπτει τον 6° μήνα μετά την ένεση της προαναφερθείσας σύνθεσης, όπου η προαναφερθείσα σύνθεση περιλαμβάνει μία ομάδα μικροσωματιδίων κατασκευασμένα από ένα συμπολυμερές του τύπου PLGA το οποίο ενσωματώνει μία δραστική ουσία στη μορφή ενός αδιάλυτου στο νερό άλατος πεπτιδίου • όπου το προαναφερθέν συμπολυμερές περαιτέρω περιλαμβάνει τουλάχιστον 75% γαλακτικό οξύ και εσωτερικό ιξώδες μεταξύ 0,1 και 0,9 dl/g, όπως μετριέται σε χλωροφόρμιο σε 25 °C και σε συγκέντρωση πολυμερούς 0,5 g/dL• όπου τα προαναφερθέντα μικροσωματίδια περαιτέρω έχουν κατανομή μεγέθους που ορίζεται ως ακολούθως: - το D (v,0,1) είναι μεταξύ 10 και 30 μικρομέτρων, - το D (v,0,5) είναι μεταξύ 30 και 70 μικρομέτρων, - το D (v,0,9) είναι μεταξύ 50 και 110 μικρομέτρων.
CY181101171T 2007-06-06 2018-11-07 Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια CY1120891T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07109767 2007-06-06
IB2007054372 2007-10-27
EP12172232.6A EP2500014B1 (en) 2007-06-06 2008-06-06 Slow release pharmaceutical composition made of microparticles
EP08763237.8A EP2164467B1 (en) 2007-06-06 2008-06-06 Slow release pharmaceutical composition made of microparticles
PCT/IB2008/052241 WO2008149320A2 (en) 2007-06-06 2008-06-06 Slow release pharmaceutical composition made of microparticles

Publications (1)

Publication Number Publication Date
CY1120891T1 true CY1120891T1 (el) 2019-12-11

Family

ID=40032512

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100060T CY1118434T1 (el) 2007-06-06 2017-01-17 Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια
CY181101171T CY1120891T1 (el) 2007-06-06 2018-11-07 Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100060T CY1118434T1 (el) 2007-06-06 2017-01-17 Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια

Country Status (32)

Country Link
US (3) US10166181B2 (el)
EP (3) EP2500014B1 (el)
JP (1) JP5419169B2 (el)
KR (1) KR101631475B1 (el)
CN (1) CN101677959B (el)
AP (1) AP3000A (el)
AU (1) AU2008259411B2 (el)
BR (1) BRPI0812250B8 (el)
CA (1) CA2688478C (el)
CO (1) CO6251234A2 (el)
CY (2) CY1118434T1 (el)
DK (2) DK2164467T3 (el)
EA (1) EA019284B1 (el)
ES (2) ES2694401T3 (el)
HK (1) HK1141737A1 (el)
HR (2) HRP20161785T1 (el)
HU (2) HUE040391T2 (el)
IL (1) IL202501A (el)
LT (2) LT2164467T (el)
MA (1) MA31422B1 (el)
ME (1) ME00959B (el)
MX (1) MX2009012856A (el)
MY (1) MY150450A (el)
NZ (1) NZ582423A (el)
PL (2) PL2164467T3 (el)
PT (2) PT2500014T (el)
RS (2) RS55591B1 (el)
SI (2) SI2164467T1 (el)
TN (1) TN2009000476A1 (el)
UA (1) UA99830C2 (el)
WO (1) WO2008149320A2 (el)
ZA (1) ZA200907940B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99830C2 (uk) 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок
PT105270B (pt) 2010-08-26 2012-05-31 Domino Ind Ceramicas S A Camada de sílica com libertação lenta de fragrância, telha cerâmica e respectivo processo de produção
CN105267153B (zh) * 2015-11-27 2018-05-11 上海苏豪逸明制药有限公司 一种曲普瑞林缓释微粒及其制备方法
CN105797134B (zh) * 2016-03-29 2019-06-14 浙江圣兆药物科技股份有限公司 一种难溶亮丙瑞林缓释制剂
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
KR102402639B1 (ko) 2017-11-24 2022-05-26 삼성전자주식회사 전자 장치 및 그의 통신 방법
CN111000798B (zh) * 2019-12-26 2021-11-23 四川恒博生物科技有限公司 一种采用原位凝胶技术的犬用非手术去势注射液
IT202000017191A1 (it) 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (el) * 1989-07-28 1992-01-15 Debiopharm Sa
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
EP0724431B1 (en) * 1993-10-22 2002-09-11 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
WO1999024061A1 (en) * 1997-11-07 1999-05-20 Chiron Corporation Method for producing igf-1 sustained-release formulations
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
US20040170665A1 (en) 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
MXPA04003433A (es) * 2001-10-10 2004-08-11 Pf Medicament Microesferas biodegradables de liberacion prolongada y metodo para preparar las mismas.
EP1617859A1 (en) * 2003-04-30 2006-01-25 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
FR2865938B1 (fr) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic Formulation retard solide comprenant de l'acetate de triptoreline
PT1968549E (pt) 2005-12-22 2014-08-29 Novartis Ag Formulação de libertação controlada compreendendo octreotida e dois ou mais polímeros de polilactídeo-co-glicolídeo
UA99830C2 (uk) 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок

Also Published As

Publication number Publication date
UA99830C2 (uk) 2012-10-10
EP2500014A2 (en) 2012-09-19
AP3000A (en) 2014-10-31
EP2500014A3 (en) 2012-11-07
HRP20161785T1 (hr) 2017-03-10
PL2500014T3 (pl) 2019-04-30
HUE031550T2 (en) 2017-07-28
AU2008259411A1 (en) 2008-12-11
AU2008259411B2 (en) 2013-10-17
RS55591B1 (sr) 2017-06-30
HUE040391T2 (hu) 2019-03-28
CA2688478C (en) 2015-10-27
US20190192423A1 (en) 2019-06-27
MY150450A (en) 2014-01-30
IL202501A (en) 2015-11-30
EA200971132A1 (ru) 2010-04-30
CA2688478A1 (en) 2008-12-11
HK1141737A1 (en) 2010-11-19
CN101677959B (zh) 2014-02-26
PT2500014T (pt) 2018-11-21
DK2500014T3 (en) 2018-12-03
PT2164467T (pt) 2017-01-13
ES2694401T3 (es) 2018-12-20
CN101677959A (zh) 2010-03-24
US20230082575A1 (en) 2023-03-16
RS58248B1 (sr) 2019-03-29
TN2009000476A1 (en) 2011-03-31
MX2009012856A (es) 2009-12-15
LT2500014T (lt) 2019-01-25
EP3431077A1 (en) 2019-01-23
KR101631475B1 (ko) 2016-06-20
EP2164467B1 (en) 2016-12-14
US20110052717A1 (en) 2011-03-03
ES2611020T3 (es) 2017-05-04
ME00959B (me) 2012-06-20
EA019284B1 (ru) 2014-02-28
BRPI0812250B1 (pt) 2020-03-03
SI2164467T1 (sl) 2017-05-31
HRP20181854T1 (hr) 2019-02-08
NZ582423A (en) 2011-10-28
MA31422B1 (fr) 2010-06-01
BRPI0812250B8 (pt) 2021-05-25
DK2164467T3 (en) 2017-01-30
KR20100023950A (ko) 2010-03-04
EP2164467A2 (en) 2010-03-24
AP2009005088A0 (en) 2009-12-31
EP2500014B1 (en) 2018-08-08
PL2164467T3 (pl) 2017-07-31
SI2500014T1 (sl) 2019-02-28
CY1118434T1 (el) 2017-06-28
CO6251234A2 (es) 2011-02-21
BRPI0812250A2 (pt) 2014-12-23
LT2164467T (lt) 2017-01-25
JP5419169B2 (ja) 2014-02-19
WO2008149320A2 (en) 2008-12-11
WO2008149320A3 (en) 2009-02-05
IL202501A0 (en) 2010-06-30
JP2010529106A (ja) 2010-08-26
ZA200907940B (en) 2010-08-25
US10166181B2 (en) 2019-01-01

Similar Documents

Publication Publication Date Title
CY1120891T1 (el) Φαρμακευτικη συνθεση αργης αποδεσμευσης κατασκευασμενη απο μικροσωματιδια
US20210290829A1 (en) Silk fibroin-based microneedles and methods of making the same
Xuan et al. Thermoreversible and injectable ABC polypeptoid hydrogels: Controlling the hydrogel properties through molecular design
Do et al. In situ forming implants for periodontitis treatment with improved adhesive properties
RU2011103437A (ru) Фармацевтическая композиция, содержащая микрочастицы с поверхностным покрытием
BR0312887A (pt) Forma de dosagem farmacêutica de múltiplos componentes
CY1116196T1 (el) Ρευστη συνθεση περιλαμβανουσα βιοσυμβατες συνθεσεις ολιγομερους-πολυμερους
CN102395354A (zh) 采用多孔性底座的微针阵列及其制造方法
JP2019502520A (ja) 薬剤放出デバイス及び使用
Lee et al. Subcutaneous vaccination using injectable biodegradable hydrogels for long-term immune response
Meng et al. Novel double-layer dissolving microneedles for transmucosal sequential delivery of multiple drugs in the treatment of oral mucosa diseases
Esposito et al. Benefits of oxygen and nitrogen plasma treatment in Vero cell affinity to poly (lactide-co-glycolide acid)
JP2016500122A5 (el)
EA201690751A1 (ru) Водорастворимая фармацевтическая пленка с повышенной стабильностью
BRPI0917819B8 (pt) compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado
US20180193536A1 (en) Bioresorbable drug delivery matrices based on cross-linked polysaccharides, dosage forms designed for delayed/controlled release
US11819578B2 (en) Nanofiber scaffolds
CN103260693B (zh) 基于丝素蛋白的微针及其制造方法
McConville et al. The effect of freeze‐drying parameters on the cure characteristics of freeze‐dried BSA‐loaded silicone elastomer
Khodaverdi et al. Preparation of smart in situ gel forming polymeric nanomicelles for prolonged release of naltrexone hydrochloride
Pazarçeviren et al. In vitro Characterization of Clinoptilolite poly caprolactone poly ethylene glycol poly caprolactone Based Bone Tissue Scaffolds
CY1114534T1 (el) Συσκευες ενεσιμης χορηγησης με παρατεταμενη αποδεσμευση
JP2016513720A (ja) 難溶性薬剤および／またはタンパク質を含むファイバ